Targeted Agent and Profiling Utilization Registry (TAPUR)
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
This trial is available at multiple Sutter locations. Please contact one of the following about ASCO TAPUR
San Francisco: Please contact ClinicalTrials@sutterhealth.org
Palo Alto/Santa Cruz: Please contact Tanya Pozniansky firstname.lastname@example.org
East Bay: Please contact James Nasman NasmanJ@sutterhealth.org and Vivian Leong, RN Leongv@sutterhealth.org
Sacramento: Please contact Rodrigi@sutterhealth.org and email@example.com
Modesto: Please contact MassonD@sutterhealth.org and PalosA@sutterhealth.org
Solano-Vallejo Cancer Center: Please contact firstname.lastname@example.org
View study details on ClinicalTrials.gov
patients 18 years old and up
Locally advanced or metastaticsolid tumor, multiple myeloma, or B cell non-Hodgkin lymphoma
American Society of Clinical Oncology
January 23, 2018
Investigator(s): Ellis C. Dillon, Ph.D.
Breast Tumor and Blood markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up
Investigator(s): Su-Ying Liang, Ph.D.